Case report of isolated synchronous multiple splenic metastases from rectal cancer
A case report and brief review of the literature

Linxian Zhao, MD, Mingxiu Sui, MD, Jiannan Li, MD, PhD, Kai Zhang, MD, PhD, * Correspondence: Kai Zhang, Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.

Abstract

Introduction: Isolated splenic metastasis emanating from colorectal cancer is an extremely rare finding, which usually indicates widely disseminated and multiple metastatic cancer. There have only been 39 cases of isolated splenic metastasis reported in the English literature to date.

Patient concerns: An 84-year-old female patient presented to the department with dark-red bloody stool that had persisted for 1 month and with an increased serum carcinoembryonic antigen (CEA) level.

Diagnoses: A colonoscopy showed a rectal mass located 3 cm from the anal margin, which was 45 mm in diameter. The patient was diagnosed with rectal cancer with splenic metastases by abdomen computed tomography.

Interventions: The patient underwent a radical resection of rectal cancer and splenectomy, and the postoperative histopathology confirmed that the splenic lesions were derived from the adenocarcinoma of the rectum.

Outcomes: After surgical treatment, the patient recovered well and was recommended for further chemotherapy.

Conclusions: In addition to revealing a rare case, we also performed a literature review, including a brief discussion about the atypical isolated splenic metastasis from colorectal cancer. Our findings enrich the database of this rare clinical entity and provide experience in the management of splenic metastasis.

Abbreviations: CEA = serum carcinoembryonic antigen, CRC = colorectal cancer, CT = computer tomography, MRI = magnetic resonance imaging.

Keywords: case report, colorectal cancer, isolated splenic metastasis, splenectomy, synchronous

1. Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth leading cause of death.\(^1\) In particular, CRC-related mortality in elderly patients is very high, even after radical surgical resection and new chemotherapy treatments.\(^2\) During clinical examination and diagnosis, most patients with CRC present tumor metastasis to regional lymph nodes, liver, lung, bone, and brain.\(^2,3\) However, both the primary and metastatic tumors of the spleen are exceedingly rare because the spleen consists of a mass of lymphoid tissue.\(^4\) More specifically, the rarity of splenic metastasis can be explained by the special anatomical structure and immunological features of the spleen.\(^5\) Splenic metastasis has been discovered from multiple primary tumors, such as liver cancer, breast cancer, lung cancer, ovarian cancer, and melanoma.\(^5\) In this context, isolated splenic metastasis derived from colorectal carcinoma is even rarer and only a few cases have been documented in the literature.\(^6\) Based on the formation time of metastasis, splenic metastasis can be divided into synchronous and metachronous metastasis. Synchronous metastasis means that the splenic lesion is discovered by imaging studies together with the primary tumor. Differently, the diagnosis of metachronous metastasis is usually made during the follow-up of patients in the postsurgical period. Most patients with splenic metastasis are asymptomatic, and only a few cases have presented with spontaneous rupture of the spleen and splenic abscess.\(^9\) For example, 1 patient presented with abdominal pain, hyperpyrexia (40°C), shaking, and chills. Further clinical examination discovered synchronous isolated splenic metastasis and a concomitant splenic abscess.\(^10\) In the present study, we reported a case of synchronous splenic metastasis in an 84-year-old female patient, which was derived from a moderately differentiated adenocarcinoma of the rectum.
2. Case report

An 84-year-old female patient came to our department with dark-red bloody stool that has persisted for 1 month. The patient also reported abdominal pain and abdominal distension. She had no symptoms of vomiting, diarrhea, fever, or weight loss, and there was no splenomegaly and hypersplenism. Her blood pressure was 125/60 mm Hg and the pulse rate was 56/min, and other physical examinations were normal. She denied any history of cancer, hypertension, and diabetes. She had a surgery history of cholecystectomy 2 years ago in our hospital. This study was approved by the ethics committee of the Second Hospital of Jilin university.

The preoperative laboratory examinations demonstrated total white blood cell count of $2.7 \times 10^9/L$ (normal: $(3.5–9.5) \times 10^9/L$) and total protein of $58.1 \text{g/L}$ (normal: $65–85 \text{g/L}$). The serum levels of alpha-fetoprotein and carbohydrate antigen 19-9 (CA19-9) were within normal limits, except for carcinoembryonic antigen (CEA), which was $57.57 \text{ng/mL}$ (normal 0–3 ng/mL).

A colonoscopy showed a rectal mass located 3 cm from the anal margin, which was 45 mm in diameter, with surface depression, erosion, and a propensity for bleeding. The tumor prevented endoscope insertion for further examination of the intestines. The histopathological results revealed that the tumor was a moderately differentiated adenocarcinoma. The abdomen enhanced computed tomography revealed wall thickening of the upper rectum (Fig. 1C) and multiple low-density shadows in the spleen (Fig. 1B), among which the largest diameter was 39.2 mm (Fig. 1A). The radiologist suspected a rectal tumor with splenic metastasis. Magnetic resonance imaging (MRI) showed irregular wall thickening of the middle and upper rectum, and the rectal lesion was about 59 mm from the anal margin. The clinical stage assessed by MRI before surgery was cT3N1 (Fig. 1D, E, and F).

Subsequently, the patient underwent a radical resection for rectal cancer and splenectomy after a series of preoperative examinations. Intraoperatively, we did not find any metastasis and dissemination to other organs. Therefore, a subtotal

Figure 1. Imaging examinations of the spleen and the rectum. (A and B) Abdomen enhanced CT showing multiple low-density shadows in the spleen (red arrow), the largest diameter of which is 39.2 mm (blue lines). (C) Abdomen CT showing wall thickening of the upper rectum (red arrow). (D) MRI (T2W-TSE-HR) showing that the cumulative length of the tumor was about 57 mm, the lower margin of the tumor was higher than the rectal ring, and the distance from the anorectal ring was about 20 mm (red arrow). (E) MRI (TSE-axial) showing irregular wall thickening of the middle and upper rectum, and the rectal lesion is about 59 mm from the anal margin (red arrow). (F) MRI (T2W-SPAIR-tra) showing a slightly high signal of the rectal lesion (red arrow). CT = computed tomography, MRI = magnetic resonance imaging.
proctectomy with side-to-side sigmoid colon–rectum anastomosis was performed. The postoperative histopathological results confirmed that the splenic lesions were consistent with adenocarcinoma of the rectum (Fig. 2), which supported the diagnosis of isolated splenic metastasis.

Intraoperatively, seventeen lymph nodes were removed, and postoperative pathology examination did not detect lymph node metastasis. The pathological stage was pT3N0M1 (stage IV). By the 15th postoperative day, the CEA level dropped to 10.13 µg/L, and the patient was finally discharged. The patient was recommended for further chemotherapy and postoperative recovery after surgery was uneventful.

3. Discussion

Tumor metastasis is a complex process, which can be influenced by multiple factors, such as anatomical structures, mechanical factors, immunological tissue microenvironment, and intrinsic characteristics of tumor cells.[11] Compared with the liver, lung, and kidney, metastatic tumors of the spleen are difficult to implant, which might be caused by its specific anatomical factors and immune surveillance functions. Especially for rectal cancer, it is difficult to form a splenic metastasis by blood vessel invasion. On the one hand, the venous blood flow above the dentate line can directly flow into the splenic vein through the inferior mesenteric artery and then enter the portal vein system. Thus, the blood flow is from the spleen to the liver, and the retrograde venous blood from the portal vein system to the spleen is very rare, making it difficult for tumor cells to reach the spleen. On the other hand, the venous blood flow below the dentate line can flow into the inferior vena cava through the internal iliac vein and internal pudendal vein. Thus, it is almost impossible to directly enter the vasculature of the spleen. In addition, the acute angulations of the spleen artery and the rhythmic contraction of the splenic capsule significantly limit the ability of the tumor embolus to implant in the spleen.[12] Besides, the reticuloendothelial system of the spleen is capable of inhibiting tumor cell proliferation. Furthermore, the lack of afferent lymphatics also limits lymphogenic metastases. More interestingly, some researchers proposed that splenic cells possess a phagocytic capability and can produce multiple anti-tumor substances, which can effectively inhibit the progression of tumors.[13] Significantly, 1 study also proposed that although disseminated cancer cells can easily reside in splenic parenchyma, the special microenvironment of the spleen may suppress the growth and progression of these cells.[14] Consequently, the splenic micrometastatic foci cannot be detected through traditional clinical methods, resulting in the clinically detectable isolated metastases of the spleen being reported as 4.4% for colon cancer and 1.6% for rectum cancer.[15] In comparison, the incidence of splenic micrometastases at autopsy is approximately 7.1%.[16]

Splenic metastasis has to be distinguished from the primary splenic lesion, such as malignant lymphoma, vascular tumors, infections disease, septic emboli, and granulomatous diseases.[4] Recently, with the development of medical imaging techniques, such as positron emission tomography (PET)-CT and PET-MRI, it has become easier to detect splenic metastases, thereby increasing their apparent incidence. Consequently, it is important to trace the patient’s disease history, in which a history of malignancy increases the possibility of splenic metastasis.[16] Interestingly, 1 study reported a patient with rectosigmoid adenocarcinoma with splenic lesions; however, the postoperative pathological diagnosis revealed a primary splenic malignant lymphoma.[17] Therefore, histopathology remains the gold standard for diagnosis.

In this study, we analyzed 39 previously published cases (22 males, 17 females; age range, 33 to 84 years; mean, 64 years) of isolated splenic metastasis derived from CRC (Table 1).[5,8,10,14,18–32,34–46] Among them, 35 cases were
## Table 1
Isolate splenic tumor metastases derived from CRC.

| No. | Age/sex | Primary tumor site | Stage | Size (cm) | Synchronous/metachronous | DFI | Solitary/multiple | CEA  (ng/mL) | Imaging | Treatment | The prognosis | Ref |
|-----|---------|---------------------|-------|-----------|--------------------------|-----|-------------------|-------------|---------|-----------|---------------|-----|
| 1   | 48/F    | Sigmoid             | III   | 0.4–3     | Metachronous             | 21  mo | Multiple          | 206.8       | PET and MRI | S, Cmt, TT | 7 mo, alive    | [18] |
| 2   | 73/M    | Hepatic flexure     | IV    | 5.7       | Synchronous              | NA  | Solitary          | 6.9         | CT      | S         | 6 mo, alive    | [19] |
| 3   | 76/F    | Descending          | III   | 1.6       | Metachronous             | 28  mo | Solitary          | 205         | CT and MRI | S         | NA          | [20] |
| 4   | 84/F    | Occum               | III   | 8         | Metachronous             | 5   mo | Solitary          | 205         | CT and MRI | S         | NA          | [21] |
| 5   | 53/M    | Sigmoid             | NA    | NA        | Metachronous             | 12  mo | Solitary          | NA          | PET      | S, Cmt    | 36 mo, died   | [22] |
| 6   | 59/M    | Descending, sigmoid | NA    | NA        | Metachronous             | 3   mo | Solitary          | NA          | PET      | S, Cmt    | 12 mo, alive  | [23] |
| 7   | 64/F    | Occum               | I     | 4.9       | Metachronous             | 6   mo | Solitary          | 38          | CT       | S, Cmt    | 10 mo, alive  | [24] |
| 8   | 62/F    | Sigmoid             | III   | 3–6       | Metachronous             | 36  mo | Multiple          | NA          | CT       | S, Cmt    | 10 mo, alive  | [25] |
| 9   | 74/M    | Descending          | IV    | 7.5–8.5   | Synchronous              | NA  | Multiple          | 242         | CT       | S, Cmt    | NA          | [26] |
| 10  | 74/M    | Occum               | III   | 7         | Metachronous             | 36  mo | Solitary          | 386.6       | PET      | S, Cmt    | 12 mo, alive  | [27] |
| 11  | 58/M    | Occum               | III   | 3.5–5.5   | Metachronous             | 20  mo | Solitary          | 4.62        | PET      | Cmt       | 7 mo, alive   | [28] |
| 12  | 70/M    | Splenic flexure     | III   | 10        | Metachronous             | 24  mo | Solitary          | NA          | CT       | S         | 12 mo, alive  | [29] |
| 13  | 73/M    | Hepatic flexure     | III   | 1.5       | Metachronous             | 62  mo | Solitary          | 132         | CT-PET   | S, Cmt    | 36 mo, alive  | [30] |
| 14  | 52/F    | Sigmoid             | III   | 4.5       | Metachronous             | 37  mo | Solitary          | 16          | PET      | S, Cmt    | NA          | [31] |
| 15  | 69/F    | Sigmoid             | II    | 4         | Metachronous             | 24  mo | Solitary          | 29          | CT       | S, Cmt    | 60 mo, alive  | [32] |
| 16  | 80/F    | Transverse          | III   | 8         | Metachronous             | 9   mo | Solitary          | 52.3        | NA       | S         | NA          | [33] |
| 17  | 54/F    | Splenic flexure     | III   | 4.5       | Metachronous             | NA  | Multiple          | 31.1        | CT       | S, Cmt    | NA          | [34] |
| 18  | 52/M    | Sigmoid, rectum     | II    | 13        | Metachronous             | 72  mo | Solitary          | 7.2         | CT       | S, Cmt    | 22 mo, alive  | [35] |
| 19  | 76/M    | Splenic flexure     | III   | 6.5       | Metachronous             | 14  mo | Solitary          | 96          | CT and PET| S         | 12 mo, alive  | [36] |
| 20  | 52/F    | Sigmoid             | NA    | NA        | Metachronous             | 24  mo | Solitary          | NA          | Rise     | CT        | 22 mo, died   | [37] |
| 21  | 62/M    | Sigmoid             | II    | 3         | Metachronous             | 25  mo | Solitary          | NA          | CT       | S         | 21 mo, alive  | [38] |
| 22  | 65/M    | Ascending           | II    | 5         | Metachronous             | 36  mo | Solitary          | 10.9        | CT       | S         | 18 mo, alive  | [39] |
| 23  | 78/F    | Rectum              | III   | 18        | Metachronous             | 48  mo | Solitary          | 64          | CT       | S         | 84 mo, alive  | [40] |
| 24  | 72/M    | Sigmoid             | III   | 9         | Metachronous             | 48  mo | Solitary          | 106         | LSS      | S         | 6 mo, alive   | [41] |
| 25  | 81/M    | Occum               | III   | NA        | Metachronous             | 30  mo | Solitary          | 7.5         | LSS      | S         | 12 mo, alive  | [42] |
| 26  | 51/F    | Rectum              | II    | 2.8       | Metachronous             | 51  mo | Solitary          | 13.5        | CT       | S         | 14 mo, alive  | [43] |
| 27  | 72/F    | Descending          | II    | 3         | Metachronous             | 144 mo | Solitary          | 223         | CT       | S         | 12 mo, alive  | [44] |
| 28  | 62/F    | Descending          | II    | 4         | Metachronous             | 42  mo | Solitary          | 22          | CT       | S         | 12 mo, alive  | [45] |
| 29  | 74/M    | Sigmoid             | II    | 9.5       | Metachronous             | 24  mo | Solitary          | 23.4        | CT       | S         | 24 mo, alive  | [46] |
| 30  | 52/M    | Ascending           | NA    | NA        | Metachronous             | 12  mo | Solitary          | NA          | US and CT| S         | 6 mo, alive   | [47] |
| 31  | 48/M    | Ascending           | NA    | NA        | Metachronous             | 24  mo | Solitary          | NA          | US and CT| S         | 3 mo, alive   | [48] |
| 32  | 33/F    | Sigmoid             | III   | 3.5       | Metachronous             | 3   mo | Solitary          | 9           | CT and MRI| S         | 12 mo, alive  | [49] |
| 33  | 51/M    | Sigmoid             | III   | 13        | Metachronous             | 72  mo | Solitary          | NA          | CT       | S         | 6 mo, alive   | [50] |
| 34  | 72/M    | Rectum              | NA    | NA        | Metachronous             | 18  mo | Solitary          | Rise        | CT       | S         | NA          | [51] |
| 35  | 59/M    | Ascending           | III   | 4         | Metachronous             | 15  mo | Solitary          | 37          | CT       | S         | 24 mo, alive  | [52] |
| 36  | 78/M    | Occum               | III   | 7         | Metachronous             | 37  mo | Solitary          | 38.6        | CT and PET| S, Cmt    | 9 mo, alive   | [53] |
| 37  | 76/F    | Descending          | IV    | 1.6       | Metachronous             | 24  mo | Solitary          | NA          | PET      | S, Cmt    | 21 mo, alive  | [54] |
| 38  | 62/M    | Sigmoid             | III   | 3.5       | Metachronous             | 23  mo | Solitary          | 2.5         | US and CT| S         | 19 mo, alive  | [55] |
| 39  | 52/F    | Descending          | IV    | 5         | Metachronous             | NA  | Solitary          | Rise        | CT       | S         | 12 mo, died   | [56] |

CEA = serum carcinoembryonic antigen, Cmt = chemotherapy, CRC = colorectal cancer, CT = computed tomography, DFI = disease-free interval between treatment of the primary tumor and diagnosis of the spleen metastasis, F = female, LSS = liver splenic scintigraphy, M = male, MRI = magnetic resonance imaging, NA = not available, PET = positron emission tomography, S = surgery, TT = target therapy, US = ultrasonography.
metachronous metastasis and only 4 cases were synchronous metastasis. Interestingly, in terms of splenectomy, there were only 4 cases of multiple metachronous splenic metastases, and most cases[40] were solitary. Here, we described the first case of a synchronic splenic metastasis from a malignant tumor of the rectum.

Among these cases, based on their primary tumor sites, we observed that the most common lesion was in the sigmoid colon (112 cases), accounting for 30.8%. In comparison, the 2 most uncommon sites were the transverse colon in 1 case and the hepatic flexure in 2 cases. Others included 6 cases in the cecum, 4 cases in the ascending colon, 3 cases in the splenic curvature, 6 cases in the descending colon, and 3 cases in the rectum. In particular, 2 patients presented with multiple primary cancers. For the 1 patient, the primary tumors were found in the descending colon and sigmoid colon together, and the tumors of the other patient were located in the sigmoid colon and rectum. Based on these findings, we deduced that the primary tumors of splenic metastasis are most commonly found in the left hemicolon in 24 cases, accounting for 61.5%, which might reflect the fact that these tumor cells can enter counter-currently into the splenic vein via the inferior mesenteric vein. In terms of primary tumor stage (1 case with stage I, 7 cases with stage II, 23 cases with stage III, 3 cases with stage IV, and 5 cases in which the stage was not mentioned), we discovered that most isolated splenic metastasis is derived from the median or advanced CRC.

Among reported cases, 29 of the 39 patients presented with an elevated CEA level. In accordance with the above results, the CEA level reached a maximum of 57.57 ng/mL in our case. In terms of cases of metachronous splenic metastasis cases, the disease-free interval ranged from 3 to 144 months (average, 31.7 months). In addition, for most of the patients, the isolated splenic metastases were found during postoperative follow-up by radiological examinations, such as abdomen computed tomography, MRI, ultrasound, fine-needle aspiration, and even fluorodeoxyglucose-PET. According to the literature, only 1 patient did not undergo curative splenectomy. For most patients, splenectomy and chemotherapy were the 2 main optimal treatment strategies.

In our case, both the primary rectal cancer and metastasis splenic lesions showed caudal type homeobox 2 (CDX2) expression (Fig. 2). CDX2, a homeobox protein, is believed to be an important factor in maintaining the intestinal phenotype and regulating colorectal tumor metastasis.[47] Importantly, we observed that splenectomy expresses special AT-rich sequence-binding protein 2 (Fig. 2), which is used as a diagnostic marker of colorectal origin cancer.[48] One study found that >93% of colorectal origin tumors expressed AT-rich sequence-binding protein 2 positive staining, which was consistent with our results.[49]

4. Conclusion

We reported a case of the rare occurrence of isolated synchronous multiple splenic metastases from rectal cancer. Our findings enrich the database of this rare clinical entity and provide experience in the management of splenic metastasis. To the best of our knowledge, splenic metastasis of colorectal carcinoma is very uncommon. With improvements in examining techniques, increasing numbers of patients with isolated splenic metastasis might be found. Over the long term, it is essential to follow-up patients with CRC postoperatively, which could effectively improve the management and prolong the survival of these patients with isolated splenic metastases. The common therapeutics options include splenectomy, chemotherapy, targeted therapy, and radiotherapy. However, to date, only a small number of cases have been reported and long-term follow-up is absent. Therefore, standardized clinical treatment strategies for splenic metastasis have not been established. In future studies, more attention should be paid to this rare entity.

Author contributions

Conceptualization: Linxian Zhao, Mingxiu Sui Investigation: Kai Zhang, Jiannan Li Methodology: Kai Zhang, Mingxiu Sui Writing – original draft: Linxian Zhao Writing – review & editing: Kai Zhang, Jiannan Li

References

[1] Svagdzys S, Lesauskaite V, Pavalkis D, et al. Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer. 2009;9:95.
[2] Roso N, Martins S, Lamelas J. Isolated splenic metastasis of colon cancer—a case report and literature review. J Coloproctol. 2012;32:89–94.
[3] TY S, TE W, SC S, et al. Synchronous isolated distant metastasis to spleen from colon adenocarcinoma. Int J Gerontol. 2009;3.
[4] Comperat E, Armelle BD, Camparo F, et al. Splenic metastases clinicopathologic presentation, differential diagnosis, and pathogenesis. Arch Pathol Lab Med. 2007;131:965–9.
[5] Kim JC, Jeong CS, Kim HC, et al. Isolated splenic metastasis from colorectal carcinoma: a case report. J Korean Med Sci. 2000;15:355–8.
[6] Griffin N, Burke C, Grant LA. Common primary tumours of the abdomen and pelvis and their patterns of tumour spread as seen on multi-detector computed tomography. Insights Imaging. 2011;2:205–14.
[7] Rizzo F, Calamia S, Mingoa G, et al. Isolated metachronous splenectomy from colon cancer: possible explanations for this rare entity. J Gastrointest Cancer. 2019;50:143–6.
[8] Tartarol ML, Cardona MA, Serrano MS, et al. Solitary splenectomy from a mucinous adenocarcinoma of the cecum. A case report. Indian J Surg. 2016;78:490–2.
[9] Achuthan R, Joseph A, Haray PN. Splenic metastasis from a rectal tumour: an unusual presentation. Ann R Coll Surg Engl. 1999;81:139.
[10] Pisano A, Ravarino A, Nieddu R, et al. Synchronous isolated splenic metastasis from colon carcinoma and concomitant splenic abscess—a case report and review of the literature. World J Gastroenterol. 2007;13:5516–20.
[11] Chambers AF, Grooss AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.
[12] Giovagnoni A, Giorgi C, Goteri G. Tumours of the spleen. Cancer Imaging. 2005;5:773–7.
[13] Okuyama T, Oya M, Ishikawa I. Isolated Splenic metastasis of sigmoid colon cancer—a case report. Japan J Clin Oncol. 2011;31:341–5.
[14] Dogan M, Ozal G, Eker N, et al. Two cases with atypical metasasis in colorectal cancer: splenic and renal metastasis. Exp Oncol. 2010;32:277–9.
[15] Berge, T. Splenic metastases. Frequencies and patterns. Acta Pathol Lab Med. 2007;131:965–9.
[16] Abi Saad GS, Hussein M, El-Saghir NS, et al. Isolated splenic metastasis from colon cancer—a case report and literature review. J Colorectal Disord. 2010;3:82–4.
[17] Wakasugi M, Yasuhara Y, Nakahara Y, et al. Primary splenic malignant lymphoma mimicking metastasis from resectosigmoid cancer: a case report. Int J Surg Case Rep. 2018;44:11–5.
[18] Hu L, Zhu JY, Fang L, et al. Isolated metachronous splenic multiple metastases after colon cancer surgery: a case report and literature review. World J Clin Cases. 2020;8:3320–8.
[19] Zhao H, Zhong W, Chen D, et al. Synchronous isolated splenic metastasis from cancer of hepatic flexure of colon: a case report. Medicine (Baltimore). 2019;98:e15016.
[20] Alfaa K, McKernan G, Skafe P, et al. Splenic metastasis in colorectal cancer. Tech Coloproctol. 2016;20:795–6.
[21] Abdou J, Omor Y, Boutayeb S, et al. Isolated splenic metastasis from colorectal cancer—a case report. J Coloproctol. 2016;20:795–6.
[22] Efared B, Mazti A, Atsame-Ebang G, et al. An unusual site of metastasis: splenic metastasis from a colon cancer. J Surg Case Rep. 2020;2016;6:riw175.
[23] Pavlović M, Sepařović R, Vulečić-Marković M. Isolated splenic metastasis from colorectal carcinoma in a high risk patient—a case report. Coll Antropol. 2011;35:1307–10.
[24] Bussi Z, Cupurdija K, Kolovrat M, et al. Isolated splenic metastasis from colon cancer—case report and literature review. Coll Antropol. 2010;34:287–90.
[25] Silen P, D’Ugo S, Benavoli D, et al. Metachronous splenectomy from colonic carcinoma five years after surgery—a case report and literature review. South Med J. 2009;102:733–5.
[26] Gasent Blesa JM, de la Morena E, Laforga Canales JB, et al. Clinical case report and literature review: metachronous colorectal splenic metastases. Clin Transl Oncol. 2008;10:445–7.

[27] Bigot P, Goodman C, Hamy A, et al. Isolated splenic metastasis from colorectal cancer: report of a case. J Gastrointest Surg. 2008;12:981–2.

[28] Montemurro S, Maselli E, Ruggieri E, et al. Isolated splenic metastasis from colon cancer. Report of a case. Tumori. 2008;94:422–5.

[29] Avninder S, Bhatnagar A, Agrawal U, et al. Isolated splenic metastasis from colorectal mucinous carcinoma. Int J Gastrointest Cancer. 2006;37:98–101.

[30] Gencosmanoglu R, Aker F, Kir G, et al. Isolated metachronous splenic metastasis from synchronous colon cancer. World J Surg Oncol. 2006;4:2.

[31] Cabanas J, da Silva RG, Zappa L, et al. Splenic metastases from mucinous neoplasms of the appendix and colon. Tumori. 2019;92:104–12.

[32] Dunbar WH BO, Morlock CG. Solitary splenic metastasis incidental to rectal carcinoma—report of a case. Mayo Clin Proc. 1969;44:40–5.

[33] Waller RM 3rd, Fajman, WA. An unusual cause of an isolated, focal splenic defect demonstrated by liver-spleen scintigraphy. Clin Nucl Med. 1982;7:5–7.

[34] Slavin JD Jr, J M, Spencer RP. Splenectomy for splenic metastasis from carcinoma of colon. Clin Nucl Med. 1986;11:491–2.

[35] Castizza P, Allen KB, Amerson JR, et al. Isolated splenic metastasis from colorectal carcinoma. South Med J. 1992;85:1003–5.

[36] Thomas SM, Fitzgerald JB, Pollack RE, et al. Isolated splenic metastases from colon carcinoma. Eur J Surg Oncol. 1993;19:485–90.

[37] Mannpriz K3, Barry AR. Solitary splenic metastasis from colorectal carcinoma. Br J Surg. 1997;84:70.

[38] Indudhara R, Vogt D, Levin HS, et al. Isolated splenic metastases from colon cancer. South Med J. 1977;90:633–6.

[39] Ishida H, Konno K, Ishida J, et al. Isolated splenic metastases. J Ultrasound Med. 1977;16:743–9.

[40] Weathers BK, Modesto VL, Gordon D. Isolated splenic metastasis from colorectal carcinoma: report of a case and review of the literature. Dis Colon Rectum. 1999;42:1345–8.

[41] Place RJ. Isolated colon cancer metastasis to the spleen. Am Surg. 2011;67:454–7.

[42] Popović M, Barisić G, Krivokapić Z. Isolated splenic metastases of colorectal carcinoma—case report and review of literature. Acta Chir Jugosl. 2008;55:73–6.

[43] Genc V, Akbari M, Karcas AS, et al. Why is isolated spleen metastasis a rare entity? Turk J Gastroenterol. 2010;21:452–3.

[44] Vega EA, Yamashita S, Shin CY, et al. Laparoscopic partial splenectomy for unknown primary cancer: a stepwise approach. Ann Surg Oncol. 2017;24:1134.

[45] Okuyama T, Oya M, Ishikawa H. Isolated splenic metastasis of sigmoid colon cancer—a case report. Jpn J Clin Oncol. 2001;31:341–5.

[46] Avesani EC, Cioffi U, Simone MD, et al. Synchronous isolated splenic metastasis from colon carcinoma. Am J Clin Oncol. 2001;24:311–2.

[47] Graule J, Uth K, Fischer E, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics. 2018;10:120.

[48] Dragomir A, de Wit M, Johansson C, et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014;141:630–8.

[49] Mezheyeuski A, Ponten F, Edqvist PH, et al. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncol. 2020;59:284–90.